MNMD News and Press, Mind Medicine (MindMed) Inc.

2024-06-28 07:24:21 ET More on Mind Medicine MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors RBC recommends buying MindMed amid psychedelic stocks sell-off (update) Read the full article on Seeking Alpha For further details see: ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will present a...

-Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation of Phase 3 program remains on schedule to begin in second half of 2024- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), ...

2024-06-18 12:31:50 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for...

Classic psychedelics are drugs that induce altered states of consciousness and intense auditory and visual hallucinations when ingested. Common classic psychedelics include psilocybin, LSD, DMT and mescaline. These drugs have been used for centuries by Indigenous peoples in spiritual ceremonie...

2024-06-08 06:47:24 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: What Moved Ma...

2024-06-05 14:37:06 ET Summary Shares of psychedelic medicine developers fall after the FDA panel votes against approving MDMA for PTSD treatment. U.S. private sector job growth falls short of expectations, raising concerns about the labor market. Wells Fargo's Chris Harvey co...

2024-06-05 11:46:27 ET Summary Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical signif...

2024-06-05 10:14:00 ET More on etc. Gold: Reversal Signals Are Increasing Ares Capital: Another Strong Quarter Despite A Decline In Net Income Regency Centers: Ongoing FFO Growth Can Lift Shares If Interest Rates Stop Rising AbbVie doses first patient in phas...